Medical Oncologist
Rafiev Dilshod Olimovich
Chemotherapy, Clinical Research
Professional summary
Diagnoses and provides conservative treatment of oncological diseases using chemotherapy, targeted therapy, and immunotherapy. Treats tumors in accordance with international clinical protocols and standards (ESMO, NCCN, ASCO, RUSSCO). Organizes and conducts clinical trials of medicinal products and medical devices in compliance with international standards ICH GCP and ISO 14155.
Areas of expertise
- Medical treatment of oncological diseases (chemotherapy, targeted, immuno-, and hormone therapy)
- Personalized selection of antitumor treatment regimens based on current clinical guidelines
- Implementation of new clinical trials and communication with international contract research organizations
- Introduction and training in Good Clinical Practice (GCP) principles
- Patient routing and development of standard operating procedures for clinical trials
Education & training
Specialization in chemotherapy (2026)
International clinical research seminar-training organized by the Pharmaceutical Product Safety Center together with USP, USA (2026)
Clinical residency in general oncology at RSNPMCOiR (2023–2025)
Student at Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russian Federation (2015–2023)
Certifications & licenses
Certificate in general oncology (2025)
Certificate in chemotherapy (2026)
Certificate from The Global Health Network's International Council for Harmonisation GCP R3 (2025)
Certificate from USP ICH Guidelines E5(R1), E6(R3), E8(R1), E17, E19 and M13A (2026)
Certificate in principles of Good Clinical Practice for medical devices ISO 14155 (2026)
Achievements & research
Clinical trials: A Phase 1 First-in-Human Study of ZE94-0605 in patients with Advanced Solid Tumors (Investigator); Clinical Investigation: Pain Mitigation in Intraperitoneal Organ Cancers: Neurolysis via Trans-vascular Energy-Based Ablation (Investigator); Single-center non-comparative prospective study to evaluate safety and efficacy of radiofrequency ablation in patients with lung tumors not eligible for surgical resection — Zidan Medical, CRC; Pilot clinical investigation to evaluate clinical performance of the Lily Device to reduce chemotherapy-induced hair loss — Luminate Medical (Investigator); ColoSeal Intraluminal Colonic Diversion System Safety and Feasibility Study 2 — Averto Medical (Investigator)
Publications: Possibilities of long-term atezolizumab immunotherapy in patients with metastatic urothelial cancer. D. Rafiev et al. Journal of Clinical Oncology (2024); The outcomes of atezolizumab therapy in combination with carboplatin and etoposide for small-cell lung cancer. D. Rafiev et al. Journal of Clinical Oncology (2024); The role of tumor markers and genetic factors in diagnosis of primary multiple malignant neoplasms of the female reproductive system (review). D.O. Rafiev et al. Journal of Theoretical and Clinical Medicine (2024); Possibilities of modern targeted therapy for metastatic colorectal cancer (review). D.O. Rafiev et al. Journal of Theoretical and Clinical Medicine (2024)
Membership: ESMO, RUSSCO, AOUZ (Association of Oncologists of Uzbekistan)